IL2 and benign prostatic hyperplasia: Together, our results provide a detailed characterization of the immune microenvironment in different volumes of the prostate and further reveal that immunosuppressants or low-dose IL-2-induced Treg- enhanced therapy can effectively inhibit prostate hyperplasia in mice, thus providing new insights for clinical BPH treatment.